Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kv3.1 and Kv3.2 potassium channels are members of the Kv3 subfamily of voltage-gated ion channels distinguished by their ability to activate and deactivate extremely rapidly at high voltage thresholds, enabling neurons to fire at very high frequencies[1][2][3][7][8]. Each channel is a tetramer, with each subunit containing six transmembrane segments (S1–S6), where S1–S6 form the voltage-sensing domain and S5–S6 create the potassium-selective pore[1][2][6]. The S4 segment carries positively charged residues that detect and respond to changes in membrane potential, triggering channel opening[1][2][6]. Kv3.1 and Kv3.2 are highly expressed in central nervous system regions that require rapid signaling, such as auditory pathways and fast-spiking interneurons[5][7]. They are critical for precise action potential repolarization, synaptic timing, and neurotransmitter release. Disruption due to mutation or dysfunction is linked to diverse neurological diseases, including epilepsy and neurodegenerative disorders[2][6]. These channels are active drug targets, and selective modulators have been structurally characterized to refine their therapeutic potential[1][4].
Positive allosteric modulation resulting in stabilized open state of the channel, enhancing fast activation and deactivation Small molecules binding to extracellular turret and voltage-sensing domains to increase potassium conductance and neuronal repolarization Blockers/antagonists may reduce current, impairing fast neuronal firing
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily C member 1 (Kv3.1) Potassium voltage-gated channel subfamily C member 2 (Kv3.2) (Kv3.1 (KCNC1 gene) Kv3.2 (KCNC2 gene)).